ClinicalTrials.gg
CompletedNCT00763061Updated Mar 2, 2010Results posted

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

A Phase 4 interventional study of Travoprost 0.004% Ophthalmic Solution (Travatan) and Timolol 0.5% Ophthalmic Solution (Timoptic) in Glaucoma, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-02.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
15th of 39
111 · median 89
Started
2006
with 2 others
Phase 4
25 of 42
none open now
Registered
19th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2006, is one of 25 in phase 4, and was the 19th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Read the detailed description

To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years;
  • IOP=16-30mmHg
  • OH or OAG with visual filed abnormality:

    1. ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p \<5% on the prepapillary diameter plot, one of which must have p \<1%,
    2. Glaucoma Hemifield Test outside normal limits,
    3. Corrected Pattern Standard Deviation with p \<5%

Exclusion criteria

Exclusion Criteria:

  • Previous damage of anterior chamber angle;
  • ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) \<1.0;
  • contact lens wearer;
  • severe central field loss;
  • uncontrolled cardiovascular, hepatic or renal disease;
  • any medication within past 1 month.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Travoprost 0.004%

    Travoprost 0.004%

    Drug: Travoprost 0.004% Ophthalmic Solution (Travatan)

  • Active comparator
    Timolol 0.5%

    Timolol 0.5%

    Drug: Timolol 0.5% Ophthalmic Solution (Timoptic)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure (IOP) at 9 AM

    Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

    Time frame: At Week 12 - At the 9 AM time point for the patient's worse eye.

  2. Week 12 - Mean IOP At 4 PM

    Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

    Time frame: At the 4 PM time point for the patient's worse eye.

Secondary outcomes

  1. Mean IOP Change From Baseline at 9 AM

    Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

    Time frame: Baseline to Week 12 - at 9 AM

  2. Mean IOP Change at 4 PM

    Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

    Time frame: Baseline to Week 12 - at 4 PM

07

Results

Posted Jan 26, 2010

Participant flow

111 patients were enrolled in this study at 4 hospitals

Participant flow — Overall Study
MilestoneTravoprost 0.004%Timolol 0.5%
Started5457
Completed4944
Not completed513

Outcome measures

PrimaryMean Intraocular Pressure (IOP) at 9 AM

Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

Time frame:
At Week 12 - At the 9 AM time point for the patient's worse eye.
Reported as:
Mean · millimeters mercury (mmHg)
Mean Intraocular Pressure (IOP) at 9 AM
millimeters mercury (mmHg)Travoprost 0.004%Timolol 0.5%
Mean Intraocular Pressure (IOP) at 9 AM16.3 ± 4.2718.1 ± 4.32
SecondaryMean IOP Change From Baseline at 9 AM

Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

Time frame:
Baseline to Week 12 - at 9 AM
Reported as:
Mean · mmHg
Mean IOP Change From Baseline at 9 AM
mmHgTravoprost 0.004%Timolol 0.5%
Mean IOP Change From Baseline at 9 AM-5.1 ± 4.35-4.4 ± 4.35
PrimaryWeek 12 - Mean IOP At 4 PM

Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

Time frame:
At the 4 PM time point for the patient's worse eye.
Reported as:
Mean · mmHg
Week 12 - Mean IOP At 4 PM
mmHgTravoprost 0.004%Timolol 0.5%
Week 12 - Mean IOP At 4 PM15.7 ± 3.1617.9 ± 4.02
SecondaryMean IOP Change at 4 PM

Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

Time frame:
Baseline to Week 12 - at 4 PM
Reported as:
Mean · mmHg
Mean IOP Change at 4 PM
mmHgTravoprost 0.004%Timolol 0.5%
Mean IOP Change at 4 PM-5.3 ± 3.69-3.7 ± 4.15

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost 0.004%—0/54 (0%)0/54 (0%)
Timolol 0.5%—0/57 (0%)0/57 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Travoprost 0.004%Timolol 0.5%Total
<=18 years213
Between 18 and 65 years333164
>=65 years192544
Sex: Female, Male
Sex: Female, Male(Participants)Travoprost 0.004%Timolol 0.5%Total
Female222648
Male323163
08

Study locations

1 site
  • Alcon Call Center
    Fort Worth, Texas 76134, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 30, 2008
Start
May 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jan 26, 2010
Last update
Mar 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00763061
Lead sponsor
Alcon Research
First posted
Sep 30, 2008
Start date
May 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jan 26, 2010
Last update
Mar 2, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion